5.4 Combination of systemic therapy and immunotherapy in HCC Before ICI immunotherapy had modified the management of HCC in the past few years, around 50% of patients with HCC received systemic therapies, generally, sorafenib or lenvatinib in the first line, followed by regorafenib, cabozantinib or ramucirumab as the second
It is also claimed to elevate the chance of ovulation and protect oocyte from DNA alterations owing to oxidative damage
Journal of the American College of Nutrition
Foa PP, Galansino G, Pozza G
Derived from a protective protein found in the human gut, BPC-157 works systemically to promote tissue repair in muscles, tendons, ligaments, and the gastrointestinal tract
doi:10.2174/1381612824666180628125200